Financial Performance in Indian Pharmaceutical Companies
Main Article Content
Abstract
The Indian pharmaceutical sector is a notable contributor to the world's healthcare industry, known for its cost-effective medicines, exports, and research and development. A retail sales tax of 10 per cent, slated to come into force in May 2017, will significantly impact companies in a fiercely competitive market by measuring their financial performance in relation to their operational efficiency, profitability, liquidity and sustainability. The present study investigates the financial performance of the selected pharmaceutical companies in India based on its profitability ratios, liquidity ratios, solvency ratios and efficiency ratios. The study's objective is to analyze the strengths and weaknesses of the financial statements of the above companies and to determine factors that affect the growth and stability of the companies. Analyses of secondary data gathered from annual reports and financial statements are combined to assess trends and performance relative to one another. It traces how these drivers of research and development expenditure, market expansion, government policy and demand across the world affect financial results. The results offer a significant insight to the investors, policy makers, researchers, and management regarding the financial well-being of Indian pharma firms and their sustainability in the long run.